Article

Bayer AG's Monsanto unit has initiated a patent infringement lawsuit against BioNTech SE and Pfizer, alleging unauthorized use of mRNA stabilization methods, and is seeking compensation from the revenues of the COVID-19 vaccine Comirnaty. Meanwhile, BioNTech has finalized its acquisition of CureVac, bolstering its oncology and mRNA capabilities, despite a recent drop in its share price. The company reported $16.7 billion in liquid assets as it prepares for an upcoming announcement on strategic priorities.